Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 13, 2025 | -$72.00 | -$0.00 | Beat |
| Aug 13, 2025 | -$72.00 | -$0.98 | Beat |
| May 15, 2025 | -$69.60 | -$6.25 | Beat |
| Nov 12, 2024 | -$129.54 | -$43.18 | Beat |
| Aug 14, 2024 | -$0.01 | -$1.73 | Miss |
| May 14, 2024 | -$0.05 | -$5.45 | Miss |